Status:
COMPLETED
Role of Pentoxifylline and Celecoxib in Parkinsonism
Lead Sponsor:
Mostafa Bahaa
Collaborating Sponsors:
Tanta University
Mohanad Omar Khrieba Clinical Pharmacy Department, Faculty of Pharmacy - Horus University
Conditions:
Parkinson Disease
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations ar...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Both male and female will be included.
- Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.
Exclusion
- Breast feeding
- Patients with significant liver and kidney function abnormalities.
- Alcohol and / or drug abusers.
- Patients with known allergy to the study medications
Key Trial Info
Start Date :
August 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 20 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05962957
Start Date
August 7 2023
End Date
September 20 2024
Last Update
August 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Mansoura University
Al Mansurah, Egypt, 35511